Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Ocelot Bio.

    Client Virtual Booth

    OCELOT BIO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Ocelot Bio
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Diego, California
    Telephone
    Telephone
    858-247-2272
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ocelotbio.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Ascites

    Details:

    OCE-205 is a therapeutic peptide with a differentiated mechanism of action. It is being evaluated in preclinical studies for the treatment of Ascites due to all etiologies except cancer.


    Lead Product(s): OCE-205

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OCE-205

    Highest Development Status: PreclinicalProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 20, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meeting®

    Details:

    OCE-205 is a mixed agonist-antagonist therapeutic peptide that has a mechanism of action designed to selectively target consequences of the systemic hemodynamic complications associated with decompensated liver cirrhosis, or ESLD.


    Lead Product(s): OCE-205

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OCE-205

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 24, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Hepatorenal Syndrome

    Details:

    OCE-205 is a peptide therapeutic with a differentiated mechanism of action (MOA) designed to selectively target serious hemodynamic complications that are the result of liver fibrosis and portal hypertension in ESLD.


    Lead Product(s): OCE-205

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OCE-205

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 22, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ocelot Bio Closes $36 Million Series A Financing, Appoints Katherine Vega Stultz as President and Chief Executive Officer

    Details:

    Proceeds will be used for lead clinical candidate, OCE-205, a peptide therapeutic with a mechanism of action designed to selectively target complications of portal hypertension that is being explored first in HRS-AKI.


    Lead Product(s): OCE-205

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: OCE-205

    Highest Development Status: Phase IProduct Type: Peptide

    Partner/Sponsor/Collaborator: RA Capital Management

    Deal Size: $36.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing March 23, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search